P2Y12 inhibitors, direct oral anticoagulants, and combination strategies challenge aspirin monotherapy as the standard antithrombotic approach for stable coronary artery disease.
Do P2Y12 inhibitors, direct oral anticoagulants, or combination strategies improve outcomes compared to aspirin monotherapy in patients with stable coronary artery disease?
Recent evidence challenges aspirin monotherapy as the standard antithrombotic approach for stable CAD, highlighting alternatives like P2Y12 inhibitors and DOACs.
Absolute Event Rate: 0% vs 0%
Stable coronary artery disease (CAD) affects around 200 million people worldwide. Recent evidence with P2Y12 inhibitors, direct oral anticoagulants, and combination strategies has challenged aspirin monotherapy as the standard antithrombotic approach.
Alzahrani et al. (Sun,) reported a other. P2Y12 inhibitors, direct oral anticoagulants, and combination strategies challenge aspirin monotherapy as the standard antithrombotic approach for stable coronary artery disease.